Efavirenz in human breast milk, mothers', and newborns' plasma

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 4, 2008, Pages 450-454

  Schneider, Serge ^a   Peltier, Alexandra ^b   Gras, Alain ^a   Arendt, Vic ^c   Karasi Omes, Christine ^b   Mujawamariwa, Anastasie ^b   Ndimubanzi, Patrick C ^b   Ndayisaba, Gilles ^b   Wennig, Robert ^a  

^a UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^b Lux Development   (Rwanda)

^c CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

Author keywords

Breast feeding; Efavirenz; HIV; Prevention of mother to child transmission

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ADULT; ARTICLE; BREAST FEEDING; BREAST MILK; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; GROUPS BY AGE; GROWTH CURVE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MILK; MOTHER; NEWBORN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOMOTOR DEVELOPMENT; PUERPERIUM; SINGLE DRUG DOSE; DISEASE TRANSMISSION; FEASIBILITY STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; PLASMA; PREGNANCY; PREGNANCY COMPLICATION; PROSPECTIVE STUDY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DISEASE TRANSMISSION, VERTICAL; FEASIBILITY STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; MALE; MILK, HUMAN; PLASMA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES;

EID: 50649088977     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31817bbc21     Document Type: Article

References (32)

1. WHO. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Towards Universal Access. Recommendations for a Public Health Approach. Geneva, Switzerland; 2006. http://www. who.int/hiv/pub/guidelines/pmtctguidelines3.pdf. Accessed May 19, 2008.
2. Palombi L, Marazzi M, Voetberg A, et al. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS. 2007;4:65-71.
3. Suksomboon N, Poolsup N, Ket-Aim S. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. J Clin Pharm Ther. 2007;32: 293-311.
4. Ogundele M, Coulter J. HIV transmission through breastfeeding: problems and prevention. Ann Trop Paediatr. 2003;23:91-106.
5. Magoni M, Okong P, Bassani L, et al. Mode of infant feeding and HIV infection in children in a program for prevention of mother-to-child transmission in Uganda. AIDS. 2005;19:433-437.
6. UNAIDS. 2006 Report on the Global AIDS Epidemic. Geneva, Switzerland: 2006.
7. Vrouenraets SM, Wit FW, van Tongeren J, et al. Efavirenz: a review. Expert Opin Pharmacother. 2007;8:851-871.
8. Lyons F, Hopkins S, Kelleher B, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med. 2006;7:255-260.
9. Rivero A, Mira JA, Pineda JA. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 2007;59: 342-346.
10. Shibuyama S, Gevorkyan A, Yoo U, et al. Understanding and avoiding antiretroviral adverse events. Curr Pharm Des. 2006;12:1075- 1090.
11. Jeantils V, Khuong M, Delassus J, et al. Efavirenz (Sustiva) in pregnancy: a study about 12 HIV patients. Gynecol Obstet Fertil. 2006;34: 593-596.
12. Bussmann H, Wester CW, Wester CN, et al. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active anti-retroviral therapy in Botswana. J Acquir Immune Defic Syndr. 2007;45: 269-273.
13. Waters L, John L, Nelson M. Non-nucleoside reverse transcriptase inhibitors: a review. Int J Clin Pract. 2007;61:105-118.
14. Watts D. Treating HIV during pregnancy: an update on safety issues. Drug Saf. 2006;29:467-490.
15. Thorne C, Newell ML. The safety of antiretroviral drugs in pregnancy. Expert Opin Drug Saf. 2005;4:323-335.
16. Funk MB, Notheis G, Schuster T, et al. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children. Eur J Med Res. 2005;10:503- 508.
17. Engelhorn C, Hoffmann F, Notheis G, et al. Effect of antiretroviral combination therapies including efavirenz in heavily pretreated HIV-infected children. Eur J Med Res. 2002;7:30-34.
18. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med. 1999;341: 1874-1881.
19. Wamalwa DC, Farquhar C, Obimbo EM, et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr. 2007;45:311-317.
20. Scherpbier HJ, Bekker V, Pajkrt D, et al. Once-daily highly active antiretroviral therapy for HIV-infected children: Safety and efficacy of an efavirenz-containing regimen. Pediatrics; 2007;119:e705- 715.
21. Lemmer P, Schneider S, Schuman M, et al. Determination of nevirapine and efavirenz in plasma using GC/MS in selected ion monitoring mode. Ther Drug Monit. 2005;27:521-525.
22. EMEA. Stocrin, European Public Assessment Report, Annexe 1. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Stoc-rin/H-250-PI-fr.pdf. Accessed February 20, 2008.
23. Ribaudo H, Clifford D, Gulick R, et al. Relationships between efavirenz pharmacokinetics, side effects, drug discontinuation, virologic response, and race: results from ACTG A5095/A5097s. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; 2004.
24. Anderson G. Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol. 2006;2:947-960.
25. Brundage R, Fletcher C, Fenton T. Efavirenz (EFV) and nelfinavir (NFV) pharmacokinetics (PK) in HIV-infected children under 2 years of age. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; 2000.
26. Mirochnick M, Stek A, Acevedo M, et al. Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life. J Acquir Immune Defic Syndr. 2005;39:189-194.
27. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004;43:1071-1087.
28. Pearce R, Gotschall R, Kearns G, et al. Cytochrome P450 involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. Drug Metab Dispos. 2001;29:1548-1554.
29. Lacroix D, Sonnier M, Moncion A, et al. Expression of CYP3A in the human liver - evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem. 1997;247: 625-634.
30. Alcorn J, McNamara P. Pharmacokinetics in the newborn. Adv Drug Deliv Rev. 2003;55:667-686.
31. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection. AIDS. 2002;16:S5-S37.
32. Giuliano M, Guidotti G, Andreotti M, et al. Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program. J Acquir Immune Defic Syndr. 2007;44:286-291.